Business
Cytek Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook
FREMONT, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions
About this update from Cytek Biosciences, Inc.
[{"type":"text","content":"FREMONT, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the fourth quarter and year ended December 31, 2025. Fourth Quarter and Full Year 2025 Highlights Total revenue for the fourth quarter was $62.1 million, an 8% increase compared to the fourth quarter of 2024, and the highest quarterly revenue achieved historically at CytekTotal revenue for the full year 2025 was $201.5 million, a 1% increase compared to the full year 2024Total recurring revenue, comprised of service and reagent revenues, grew 21% in 2025 compared to 2024, reaching 34% of total revenueAdjusted EBITDA in the year ended December 31, 2025 was $5.0 million, compared to $22.4 million for the full year 2024Expanded to a total installed base of 3,664 Cytek instruments, with 630 total instruments placed during 2025. Unit placements of Cytek’s Aurora CS system grew 22% in 2025 over the prior year.Launched the Cytek Aurora™ Evo system, a new full spectrum flow cytometer that improves on Cytek’s flagship Aurora system and offers faster sample throughput, automated instrument startup and shutdown, enhanced resolution for small particle detection, and data harmonization Launched the Cytek® Muse® Micro cell analyzer, which was awarded the 2025 Biotech Breakthrough Award for Drug Discovery Solution of the Year and highlights Cytek’s commitment to making cell analysis accessible, intuitive and cost-effective for laboratories of all sizes “We were pleased by our fourth quarter revenue growth, which marked a clear acceleration versus the prior year and a continuation of the positive trends we saw earlier in 2025. Our revenue performance in the quarter was driven by strong momentum in FSP instrument sales in all major markets worldwide alongside sustained growth in our recurring revenue streams. We were especially encouraged to see improving instrument demand in both the US and EMEA,” said Dr. Wenbin Jiang, CEO of Cytek Biosciences. “This broad-based execution positions us well for 2026, where our priorities will continue to focus on the growth of our high-margin recurring revenue lines, accelerating the adoption of our instrument platforms, advancing a pipeline of innovative new products, and delivering profitable, durable growth...